prof. Eva Van Braeckel

Merel Wauters (UGent) , Laura Bollé (UGent) , Sara Van den Bossche, Lucia Grassi (UGent) , Delphi Van Haver (UGent) , Sara Dufour (UGent) , Simon Devos (UGent) , Francis Impens (UGent) , Eva Van Braeckel (UGent) , Anna K.H. Hirsch, et al.

(2025)

Add to list

Correlation between patient-derived intestinal organoids and clinical responses to CFTR modulators in people with cystic fibrosis homozygous for F508del

Noelia Rodriguez Mier, Senne Cuyx, Kris De Boeck, Marijke Proesmans, Mieke Boon, Lieven Dupont, Kaline Arnauts, Elke De Wachter, Stephanie Van Biervliet (UGent) , Monique Lequesne, et al.

(2025) JOURNAL OF CYSTIC FIBROSIS. 24(5). p.939-945

Add to list

Journal Article
A1
open access

Physical activity and physical function one year after hospital discharge for COVID-19

Eva Arents (UGent) , Fien Hermans (UGent) , Lies Glorie, Bihiyga Salhi, Cedric Bosteels (UGent) , Eric Derom (UGent) , Wim Janssens, Eva Van Braeckel (UGent) , Natalie Lorent, Yannick Vande Weygaerde (UGent) , et al.

(2025) JOURNAL OF CLINICAL MEDICINE. 14(17).

Add to list

Shifts in systemic inflammatory profiles on elexacaftor/tezacaftor/ivacaftor predict clinical outcomes in cystic fibrosis

Leander Jonckheere (UGent) , Lieve Vande Sande, Iris Janssens (UGent) , Yannick Vande Weygaerde (UGent) , Stephanie Van Biervliet (UGent) , Heidi Schaballie (UGent) , Petra Schelstraete (UGent) , Tania Maes (UGent) , Cedric Bosteels (UGent) and Eva Van Braeckel (UGent)

(2025) JOURNAL OF CYSTIC FIBROSIS. In Journal of Cystic Fibrosis 24(Supplement 1). p.S20-S20

Academic Bibliography

prof. Eva Van Braeckel

Effects of elexacaftor/tezacaftor/ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis

Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function : insights from a European multicenter survey

Pulmonary mycoses : a clinical perspective

Allergic bronchopulmonary aspergillosis

Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population

Rethinking CFTR variant responsiveness : differential responses to vanzacaftor and elexacaftor

Identification of DksA as a novel pro-inflammatory mediator of <i>Pseudomonas aeruginosa</i> under conditions mimicking chronic cystic fibrosis lung infection

Correlation between patient-derived intestinal organoids and clinical responses to CFTR modulators in people with cystic fibrosis homozygous for F508del

Physical activity and physical function one year after hospital discharge for COVID-19

Shifts in systemic inflammatory profiles on elexacaftor/tezacaftor/ivacaftor predict clinical outcomes in cystic fibrosis

Contents

Support

Contact